Logo

Durect's Posimir (bupivacaine solution) Receives the US FDA's Approval for the Treatment of Post-Surgical Pain

Share this

Durect's Posimir (bupivacaine solution) Receives the US FDA's Approval for the Treatment of Post-Surgical Pain

Shots:

  • The approval is based on clinical trial involves assessing Posimir (4mg) vs PBO (12mg) in patients in patients undergoing arthroscopic subacromial decompression surgery with an intact rotator cuff for the first 72hrs.
  • The results demonstrated an improvement in both primary outcome measures i.e. 20% reduction in mean pain intensity on a 0-10 point pain scale; 67% reduction in IV morphine-equivalent rescue opioid use
  • Posimir is the only approved sustained-release bupivacaine product indicated for up to 72hours of post-surgical analgesia from a single application

 ­ Ref: Durect | Image: Reedland Capital Partners

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions